<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>ETF Trends &#187; IBB</title>
	<atom:link href="http://www.etftrends.com/tag/ibb/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.etftrends.com</link>
	<description>Setting the Pace for Exchange Traded Funds</description>
	<lastBuildDate>Sat, 11 Feb 2012 14:09:57 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.9.2</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Biotech ETFs Break Out</title>
		<link>http://www.etftrends.com/2012/01/biotech-etfs-break-out/</link>
		<comments>http://www.etftrends.com/2012/01/biotech-etfs-break-out/#comments</comments>
		<pubDate>Thu, 19 Jan 2012 14:45:51 +0000</pubDate>
		<dc:creator>John Spence</dc:creator>
				<category><![CDATA[Feature Stories]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[BBH]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[FBT]]></category>
		<category><![CDATA[IBB]]></category>
		<category><![CDATA[XBI]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=74303</guid>
		<description><![CDATA[The rally in biotechnology exchange traded funds is going vertical in early 2012 with the sector&#8217;s largest ETF posting a gain of 20% over the past three months.
The $1.5 billion iShares Nasdaq Biotechnology Index Fund (IBB) is breaking out to new all-time highs. The ETF is up 9.6% year to date, compared with a 4.1% [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2012/01/biotech-etfs-break-out/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Dividends, Safety Drive 2011 Sector ETF Winners</title>
		<link>http://www.etftrends.com/2011/12/dividends-safety-drive-2011-sector-etf-winners/</link>
		<comments>http://www.etftrends.com/2011/12/dividends-safety-drive-2011-sector-etf-winners/#comments</comments>
		<pubDate>Mon, 05 Dec 2011 15:27:57 +0000</pubDate>
		<dc:creator>Tom Lydon</dc:creator>
				<category><![CDATA[Feature Stories]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Consumer Staples]]></category>
		<category><![CDATA[IBB]]></category>
		<category><![CDATA[Lead]]></category>
		<category><![CDATA[Utilities]]></category>
		<category><![CDATA[XLP]]></category>
		<category><![CDATA[XLU]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=71030</guid>
		<description><![CDATA[With less than a month left in 2011, the best performers in sector exchange traded funds this year track industries known for dividends and some insulation from economic cycles. They include ETFs tracking utilities, pharmaceuticals and biotechnology, and consumer staples.
Utilities Select Sector SPDR Fund (NYSEArca: XLU) is up 14.2% year to date while the S&#38;P [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2011/12/dividends-safety-drive-2011-sector-etf-winners/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Biotech ETFs Mixed After Gilead Subpoena</title>
		<link>http://www.etftrends.com/2011/06/biotech-etfs-mixed-after-gilead-subpoena/</link>
		<comments>http://www.etftrends.com/2011/06/biotech-etfs-mixed-after-gilead-subpoena/#comments</comments>
		<pubDate>Mon, 13 Jun 2011 17:53:52 +0000</pubDate>
		<dc:creator>Tom Lydon</dc:creator>
				<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[BBH]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[IBB]]></category>
		<category><![CDATA[PBE]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=56144</guid>
		<description><![CDATA[Biotechnology exchange traded funds were mixed Monday after sector bellwether Gilead Sciences (NasdaqGS: GILD) disclosed it has received a subpoena from the U.S. Department of Justice.
Gilead shares were down nearly 1% but pared their earlier loss after the company late Friday said it has received a request for information from the U.S. Attorney&#8217;s Office for [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2011/06/biotech-etfs-mixed-after-gilead-subpoena/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Biotech ETFs: Orexigen Hit By Regulatory Hammer</title>
		<link>http://www.etftrends.com/2011/06/biotech-etfs-orexigen-hit-by-regulatory-hammer/</link>
		<comments>http://www.etftrends.com/2011/06/biotech-etfs-orexigen-hit-by-regulatory-hammer/#comments</comments>
		<pubDate>Fri, 03 Jun 2011 19:47:41 +0000</pubDate>
		<dc:creator>Tom Lydon</dc:creator>
				<category><![CDATA[All]]></category>
		<category><![CDATA[Current Affairs]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[FBT]]></category>
		<category><![CDATA[IBB]]></category>
		<category><![CDATA[IHE]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PPH]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=55162</guid>
		<description><![CDATA[Biotech sector and related exchange traded funds (ETFs) trade lower as one drug maker garners notoriety after regulatory hurdles puts a hold on the advancement of an anticipated diet pill.

iShares Nasdaq Biotechnology (NYSEArca: IBB) is down 0.83%.
First Trust Amex Biotech Index Fund (NYSEAca: FBT) is down 0.74%.
iShares Dow Jones U.S. Pharmaceutical Index Fund (NYSEArca: IHE) [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2011/06/biotech-etfs-orexigen-hit-by-regulatory-hammer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Teva, Cephalon Boost Biotech ETFs</title>
		<link>http://www.etftrends.com/2011/05/teva-cephalon-boost-biotech-etfs/</link>
		<comments>http://www.etftrends.com/2011/05/teva-cephalon-boost-biotech-etfs/#comments</comments>
		<pubDate>Mon, 02 May 2011 15:45:58 +0000</pubDate>
		<dc:creator>John Spence</dc:creator>
				<category><![CDATA[All]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[FBT]]></category>
		<category><![CDATA[IBB]]></category>
		<category><![CDATA[XBI]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=52575</guid>
		<description><![CDATA[Biotechnology exchange traded funds (ETFs) rallied to open the week after Teva Pharmaceutical (NasdaqGS: TEVA) said it’s buying Cephalon (NasdaqGS: CEPH) for $6.8 billion in a blockbuster sector deal.
The combined company would represent about $7 billion in annual sales. Shares of Teva and Cephalon were both up more than 3% in recent trading.
&#8220;This is transforming [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2011/05/teva-cephalon-boost-biotech-etfs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Biogen Earnings, Drug Data to Lift Biotech ETFs</title>
		<link>http://www.etftrends.com/2011/04/biogen-earnings-drug-data-to-lift-biotech-etfs/</link>
		<comments>http://www.etftrends.com/2011/04/biogen-earnings-drug-data-to-lift-biotech-etfs/#comments</comments>
		<pubDate>Thu, 21 Apr 2011 12:55:22 +0000</pubDate>
		<dc:creator>John Spence</dc:creator>
				<category><![CDATA[All]]></category>
		<category><![CDATA[Current Affairs]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[BBH]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[IBB]]></category>
		<category><![CDATA[XBI]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=51598</guid>
		<description><![CDATA[Biogen (NasdaqGS: BIIB) shares jumped more than 20% in premarket action Thursday after the company reported higher-first quarter profit and released encouraging data on an experimental multiple sclerosis drug.
The data on the drug, BG-12, was “very competitive versus other approved and pipeline MS therapies” and the results are “a significant catalyst for Biogen shares,” said [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2011/04/biogen-earnings-drug-data-to-lift-biotech-etfs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>ETFs And A Global Approach Help Investors Access Biotech</title>
		<link>http://www.etftrends.com/2011/03/etfs-and-a-global-approach-help-investors-access-biotech/</link>
		<comments>http://www.etftrends.com/2011/03/etfs-and-a-global-approach-help-investors-access-biotech/#comments</comments>
		<pubDate>Fri, 11 Mar 2011 09:00:37 +0000</pubDate>
		<dc:creator>Tom Lydon</dc:creator>
				<category><![CDATA[All]]></category>
		<category><![CDATA[Current Affairs]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[FBT]]></category>
		<category><![CDATA[IBB]]></category>
		<category><![CDATA[XBI]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=47499</guid>
		<description><![CDATA[Investing in biotech stocks and companies is so much like gambling, the risk is sometimes not worth it. Why not mitigate the risk and invest in an exchange traded fund (ETF) instead, which will give investors exposure to several companies at once.[Dissipate The Risk In Biotechnology With ETFs.]
According to MinyanVille, the process of New Drug [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2011/03/etfs-and-a-global-approach-help-investors-access-biotech/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>5 Biotechnology ETFs to Play Innovation</title>
		<link>http://www.etftrends.com/2011/02/5-biotechnology-etfs-play-innovation/</link>
		<comments>http://www.etftrends.com/2011/02/5-biotechnology-etfs-play-innovation/#comments</comments>
		<pubDate>Tue, 22 Feb 2011 22:00:10 +0000</pubDate>
		<dc:creator>Tom Lydon</dc:creator>
				<category><![CDATA[All]]></category>
		<category><![CDATA[Current Affairs]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[BBH]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[FBT]]></category>
		<category><![CDATA[Health Care]]></category>
		<category><![CDATA[HOLDRs]]></category>
		<category><![CDATA[Hot Story]]></category>
		<category><![CDATA[IBB]]></category>
		<category><![CDATA[PBE]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[XBI]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=46796</guid>
		<description><![CDATA[While the broader market has picked up its pace, the biotechnology sector has not seen a similar surge in performance. Still, investors should keep in mind the various biotech exchange traded fund (ETF) plays to stay positioned for a resurgence in the sector.
Currently, the biotech industry is full of fast-growing and very profitable companies; however, [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2011/02/5-biotechnology-etfs-play-innovation/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Sector ETFs to Play the State of the Union Address</title>
		<link>http://www.etftrends.com/2011/01/sector-etfs-play-state-union-address/</link>
		<comments>http://www.etftrends.com/2011/01/sector-etfs-play-state-union-address/#comments</comments>
		<pubDate>Wed, 26 Jan 2011 20:00:06 +0000</pubDate>
		<dc:creator>Tom Lydon</dc:creator>
				<category><![CDATA[All]]></category>
		<category><![CDATA[Current Affairs]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[Socially Responsible ETFs]]></category>
		<category><![CDATA[Aerospace & Defense]]></category>
		<category><![CDATA[Alternative Energy]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Clean Energy]]></category>
		<category><![CDATA[Energy]]></category>
		<category><![CDATA[FBT]]></category>
		<category><![CDATA[FXH]]></category>
		<category><![CDATA[GEX]]></category>
		<category><![CDATA[Green ETFs]]></category>
		<category><![CDATA[GRID]]></category>
		<category><![CDATA[Health Care]]></category>
		<category><![CDATA[Hot Story]]></category>
		<category><![CDATA[IBB]]></category>
		<category><![CDATA[IHF]]></category>
		<category><![CDATA[Infrastructure]]></category>
		<category><![CDATA[ITA]]></category>
		<category><![CDATA[IYW]]></category>
		<category><![CDATA[NASI]]></category>
		<category><![CDATA[PBW]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PJP]]></category>
		<category><![CDATA[PPA]]></category>
		<category><![CDATA[QQEW]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[XBI]]></category>
		<category><![CDATA[XLK]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=45357</guid>
		<description><![CDATA[In his State of the Union address Tuesday, President Barack Obama touched upon the major problems that have crippled our nation and offered an essential directive to invest in our future. If Obama&#8217;s proposals become actualities, something that&#8217;s not necessarily a certainty, then the exchange traded funds (ETFs) below could make moves.
President Obama stressed the [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2011/01/sector-etfs-play-state-union-address/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Dissipate the Risk In Biotechnology With ETFs</title>
		<link>http://www.etftrends.com/2011/01/dissipate-risk-biotechnology-etfs/</link>
		<comments>http://www.etftrends.com/2011/01/dissipate-risk-biotechnology-etfs/#comments</comments>
		<pubDate>Tue, 18 Jan 2011 22:00:17 +0000</pubDate>
		<dc:creator>Tom Lydon</dc:creator>
				<category><![CDATA[All]]></category>
		<category><![CDATA[Current Affairs]]></category>
		<category><![CDATA[Long-Short ETFs]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[BIB]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[BIS]]></category>
		<category><![CDATA[FBT]]></category>
		<category><![CDATA[Health Care]]></category>
		<category><![CDATA[IBB]]></category>
		<category><![CDATA[XBI]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=44690</guid>
		<description><![CDATA[The biotechnology sector offers investors the opportunity to bet big and win big, but the potential downside can make a huge dent in your wallet. Perhaps a biotech exchange traded fund (ETF) is more to your liking?
The largest and most liquid broad-based biotech sector iShares Nasdaq Biotechnology (NASDAQ: IBB), which reflects the performance of the [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2011/01/dissipate-risk-biotechnology-etfs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Play the Booming Biotech Sector With ETFs</title>
		<link>http://www.etftrends.com/2010/12/play-booming-biotech-sector-etfs/</link>
		<comments>http://www.etftrends.com/2010/12/play-booming-biotech-sector-etfs/#comments</comments>
		<pubDate>Tue, 21 Dec 2010 23:00:29 +0000</pubDate>
		<dc:creator>Tom Lydon</dc:creator>
				<category><![CDATA[All]]></category>
		<category><![CDATA[Current Affairs]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[BBH]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Health Care]]></category>
		<category><![CDATA[Hot Story]]></category>
		<category><![CDATA[IBB]]></category>
		<category><![CDATA[IHE]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[XBI]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=43168</guid>
		<description><![CDATA[Economic downturn? What economic downturn? Despite lackluster economic growth, biotechnology exchange traded funds (ETFs) have managed to notch solid performance this year.
In the United Kingdom alone, the bioscience sector has exploded. It now includes 942 companies, with 345 involved in the development, manufacture or sales of therapeutic products, according to PharmaLive. The biotech sector also [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2010/12/play-booming-biotech-sector-etfs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>What ETFs Are Doing Ahead of Fed Meeting</title>
		<link>http://www.etftrends.com/2010/12/what-etfs-are-doing-ahead-fed-meeting/</link>
		<comments>http://www.etftrends.com/2010/12/what-etfs-are-doing-ahead-fed-meeting/#comments</comments>
		<pubDate>Tue, 14 Dec 2010 16:30:05 +0000</pubDate>
		<dc:creator>Tom Lydon</dc:creator>
				<category><![CDATA[All]]></category>
		<category><![CDATA[Bond ETFs]]></category>
		<category><![CDATA[Currency ETFs]]></category>
		<category><![CDATA[Current Affairs]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[Asia]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[BWX]]></category>
		<category><![CDATA[Consumer Staples]]></category>
		<category><![CDATA[Emerging Markets]]></category>
		<category><![CDATA[Federal Reserve]]></category>
		<category><![CDATA[FXG]]></category>
		<category><![CDATA[Health Care]]></category>
		<category><![CDATA[Hot Story]]></category>
		<category><![CDATA[IBB]]></category>
		<category><![CDATA[International Treasury Bonds]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Retail]]></category>
		<category><![CDATA[South Korea]]></category>
		<category><![CDATA[U.S. Dollar]]></category>
		<category><![CDATA[UUP]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=42972</guid>
		<description><![CDATA[Most exchange traded funds (ETFs) are keeping gains tempered this morning as the markets await word about what the Federal Reserve will do about interest rates. While they wait, investors seem to be taking comfort in a solid retail report.

The Commerce Department reported U.S. retail sales increased 0.8% in November, up for a fifth consecutive [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2010/12/what-etfs-are-doing-ahead-fed-meeting/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Why Health Care ETFs May Be In the Clear</title>
		<link>http://www.etftrends.com/2010/11/why-health-care-etfs-may-be-in-the-clear/</link>
		<comments>http://www.etftrends.com/2010/11/why-health-care-etfs-may-be-in-the-clear/#comments</comments>
		<pubDate>Wed, 10 Nov 2010 19:00:49 +0000</pubDate>
		<dc:creator>Tom Lydon</dc:creator>
				<category><![CDATA[All]]></category>
		<category><![CDATA[Current Affairs]]></category>
		<category><![CDATA[Long-Short ETFs]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[FBT]]></category>
		<category><![CDATA[Health Care]]></category>
		<category><![CDATA[Hot Story]]></category>
		<category><![CDATA[IBB]]></category>
		<category><![CDATA[IHF]]></category>
		<category><![CDATA[IXJ]]></category>
		<category><![CDATA[IYH]]></category>
		<category><![CDATA[PBE]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PJP]]></category>
		<category><![CDATA[PTH]]></category>
		<category><![CDATA[RXD]]></category>
		<category><![CDATA[RXL]]></category>
		<category><![CDATA[RYH]]></category>
		<category><![CDATA[VHT]]></category>
		<category><![CDATA[XBI]]></category>
		<category><![CDATA[XLV]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=40871</guid>
		<description><![CDATA[After the Democrats lost some seats in the mid-term elections, you might be wondering whether health care revenue and exchange traded funds (ETFs) will be affected by the shift. Some don&#8217;t believe there&#8217;s anything to worry about for a while.
First, with most corporations backing major Congressional players, it is almost certain that the medical industry [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2010/11/why-health-care-etfs-may-be-in-the-clear/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Biotech ETFs May Soon Face Challenges</title>
		<link>http://www.etftrends.com/2010/11/biotech-etfs-may-soon-face-challenges/</link>
		<comments>http://www.etftrends.com/2010/11/biotech-etfs-may-soon-face-challenges/#comments</comments>
		<pubDate>Sat, 06 Nov 2010 20:00:26 +0000</pubDate>
		<dc:creator>Tom Lydon</dc:creator>
				<category><![CDATA[All]]></category>
		<category><![CDATA[Current Affairs]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[FBT]]></category>
		<category><![CDATA[Health Care]]></category>
		<category><![CDATA[Hot Story]]></category>
		<category><![CDATA[IBB]]></category>
		<category><![CDATA[XBI]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=40680</guid>
		<description><![CDATA[The Republican takeover of the House this week could have a negative impact on biotechnology exchange traded funds (ETFs).
Kenneth Chang for The New York Times reports that research and development at nonmilitary agencies — including those that sponsor science and health research — would fall 12.3 %, to $57.8 billion, down from President Obama’s requested [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2010/11/biotech-etfs-may-soon-face-challenges/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Biotech ETFs Readying to Deliver the Goods</title>
		<link>http://www.etftrends.com/2010/11/biotech-etfs-readying-deliver-goods/</link>
		<comments>http://www.etftrends.com/2010/11/biotech-etfs-readying-deliver-goods/#comments</comments>
		<pubDate>Tue, 02 Nov 2010 20:00:53 +0000</pubDate>
		<dc:creator>Tom Lydon</dc:creator>
				<category><![CDATA[All]]></category>
		<category><![CDATA[Current Affairs]]></category>
		<category><![CDATA[Long-Short ETFs]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[BIB]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[FBT]]></category>
		<category><![CDATA[Health Care]]></category>
		<category><![CDATA[Hot Story]]></category>
		<category><![CDATA[IBB]]></category>
		<category><![CDATA[XBI]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=40365</guid>
		<description><![CDATA[Biotechnology exchange traded funds (ETFs) could be poised to deliver the goods as an aging population and demand for new treatments stokes growth in the sector.
A slew of factors are driving the sector these days, explains PR.com. They include:

Increasing demand for biotechnology drugs with enhanced efficiency, safety and popularity.
Revision of regulations and standards in favor [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2010/11/biotech-etfs-readying-deliver-goods/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

